scholarly journals Using Large Institutional or National Databases to Evaluate Prostate Cancer Outcomes and Patterns of Care: Possibilities and Limitations

2011 ◽  
Vol 11 ◽  
pp. 147-160 ◽  
Author(s):  
Daniel Su ◽  
Thomas L. Jang
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cancer Research ◽  
Side Effects ◽  
Patterns Of Care ◽  
Cancer Outcomes ◽  
Large Databases ◽  
Prostate Cancer Research ◽  
National Databases

Prostate cancer is the most common non–skin-related cancer in men. With advances in technology, the care and treatment for men with this disease continues to become more complex. Large databases offer researchers a unique opportunity to conduct prostate cancer research in various areas, and provide important information that helps patients and providers determine prognosis after treatment. Furthermore, the studies using these databases may provide information on how side effects from various treatments can affect one's quality of life. Finally, information from these datasets can help to identify factors that determine why patients receive the treatments they do. Despite this, these databases are not without limitations. In this review, we discuss various available, national, multicenter, and institutional databases in the context of prostate cancer research, citing numerous important studies that have impacted on our understanding of prostate cancer outcomes.

scholarly journals Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study

2010 ◽  
Vol 107 (8) ◽  
pp. 1223-1231 ◽  
Author(s):  
Melissa S.Y. Thong ◽  
Lonneke van de Poll-Franse ◽  
Richard M. Hoffman ◽  
Peter C. Albertsen ◽  
Ann S. Hamilton ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
Health Related Quality ◽  
Cancer Outcomes ◽  
Related Quality ◽  
Health Related ◽  
Outcomes Study

scholarly journals Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis

2019 ◽  
Vol 58 (6) ◽  
pp. 916-925 ◽  
Author(s):  
Almut Dutz ◽  
Linda Agolli ◽  
Michael Baumann ◽  
Esther G. C. Troost ◽  
Mechthild Krause ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Side Effects ◽  
Proton Beam ◽  
Proton Beam Therapy ◽  
Matched Pair ◽  
Matched Pair Analysis ◽  
Pair Analysis ◽  
Late Side

scholarly journals A comparison of side-effects and quality-of-life in patients operated on for prostate cancer with and without salvage radiation therapy

2020 ◽  
Vol 54 (5) ◽  
pp. 393-400
Author(s):  
Karin Braide ◽  
Jon Kindblom ◽  
Ulrika Lindencrona ◽  
Marianne Månsson ◽  
Jonas Hugosson
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Radiation Therapy ◽  
Side Effects ◽  
Salvage Radiation Therapy

scholarly journals A Cross-Sectional Comparison of Quality of Life Between Physically Active and Underactive Older Men With Prostate Cancer

2016 ◽  
Vol 24 (4) ◽  
pp. 642-648 ◽  
Author(s):  
Samara Boisen ◽  
Chris Krägeloh ◽  
Daniel Shepherd ◽  
Clare Ryan ◽  
Jonathan Masters ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Side Effects ◽  
Cancer Survivors ◽  
Specific Antigen ◽  
Well Being ◽  
Older Men ◽  
Physically Active ◽  
Prostate Cancer Survivors

Men with prostate cancer experience many side effects and symptoms that may be improved by a physically active lifestyle. It was hypothesized that older men with prostate cancer who were physically active would report significantly higher levels of quality of life (QOL) as assessed by the WHOQOL-BREF and the WHOQOL-OLD. Of the 348 prostate cancer survivors who were invited to participate in the present postal survey, 137 men returned the questionnaires. Those who were physically active had significantly lower prostate specific antigen (PSA) scores and higher social participation than those insufficiently active. These findings offer some support for the benefits of physical activity (PA) within the prostate cancer population in managing the adverse side effects of their treatments on aspects of their QOL. Future research should more closely examine what types of PA best promote improvements in varying aspects of QOL and psychological well-being for prostate cancer survivors.

Quality of life of men treated for localized prostate cancer: outcomes at 6 and 12 months

2008 ◽  
Vol 17 (5) ◽  
pp. 509-517 ◽  
Author(s):  
Elise L. Lev ◽  
Lucille Sanzero Eller ◽  
Glen Gejerman ◽  
John Kolassa ◽  
Joan Colella ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Localized Prostate Cancer ◽  
Cancer Outcomes

On Cancer Nanotechnology

2010 ◽  
Vol 441 ◽  
pp. 307-332
Author(s):  
Rita Bosetti ◽  
Lode Vereeck
Keyword(s):  
Quality Of Life ◽  
Cancer Research ◽  
Side Effects ◽  
Cancer Biology ◽  
Causes Of Death ◽  
Poor Quality ◽  
Therapeutic Agents ◽  
Target Cells ◽  
Patients Experience

Although governments invest billions of dollars in cancer research, cancer remains one of the major causes of death worldwide (Liu et al., 2007). During the last decades, outstanding results have been attained in fundamental cancer biology but, unfortunately, they have not been translated in even distantly comparable progressions in the clinic. The main reason for this gap being the inability to administer therapeutic agents so that they can reach target cells without or with minimal side-effects (Ferrari, 2005). Today, scientists are faced with the recognition that very few molecules reach the desired locations and thus fail to selectively reach the target cells. Consequently, patients experience a very poor quality of life (Ferrari, 2004; Ferrari, 2005; Chan, 2006).

Shifting patterns of care in localized prostate cancer: Impact on patient reported outcome measures (PROMs).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e16603-e16603
Author(s):  
Brendan James Connell ◽  
Rima Patel ◽  
Hong Chang ◽  
Tony Luongo ◽  
Liyan Zhuang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Radiation Therapy ◽  
Tertiary Care ◽  
Bowel Function ◽  
Low Risk ◽  
Patterns Of Care ◽  
Localized Prostate Cancer ◽  
Patient Reported

e16603 Background: In localized prostate cancer (LPC), evolving therapeutic techniques and patterns of care including the use of active surveillance (AS) are expected to have had a positive effect on quality of life. A longitudinal assessment of changes in disease presentations and patterns of care in LPC correlated to PROMs is required. Methods: All cases of LPC (T1-T4, N0-N1) at a tertiary care institution were identified between 2005 and 2015. Two cohorts (C1: 2005-10, C2: 2010-15) with a minimum of 2-years follow-up, were identified. Demographics, disease characteristics and management strategies were compared across cohorts. To assess PROMs, a one-time questionnaire including EPIC-26 and Clark’s Quality of Life was administered. Domain summary scores were compared across cohorts. Results: 873 patients met criteria [C1: 422, C2: 535]. Demographics were well balanced (p = 0.10): overall 64.1% white, 12.7% AA, 12.7% Asian. D’Amico risk scores increased over time (p = 0.001): fewer low-risk cases [C1: 49.2%, C2: 43.7%], higher intermediate-risk disease [C1: 34.6%, C2: 40.3%], and stable high-risk proportions [C1: 15.7%, C2: 14.9%]. Patterns of care shifted significantly (p = 0.005) with a marked decrease in radiation therapy [C1: 25.7%, C2: 15.4%], unchanged radical prostatectomy rates [C1: 47.9%, C2: 51.0%], a shift to robotic surgery [C1: 23.8%, C2: 90.3%], and an increase in AS [C1: 21.8%, C2: 30.8%], particularly in low-risk disease [C1: 32.4%, C2: 53.5%]. Questionnaire response rate was 45.1%. Using multivariate regression, C2 demonstrated an improvement in bowel function (p = 0.031) but not in urinary, sexual, or psychometric scores. Conclusions: Notwithstanding an increase in AS utilization for low-risk disease, an improvement in bowel function and lack of improvement in urinary/sexual PROMs in LPC across time-cohorts was noted. This may be accounted for by increased presentations of higher-risk disease managed with robotic surgeries at the expense of radiation therapy. Although time-length bias can influence comparisons, given national trends with a similar shift in presentation and care patterns, these PROM correlations are likely generalizable to the U.S. population.

scholarly journals Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol

BMJ Open ◽  
2019 ◽  
Vol 9 (9) ◽  
pp. e030218
Author(s):  
Klara Kvorning Ternov ◽  
Jens Sønksen ◽  
Mikkel Fode ◽  
Henriette Lindberg ◽  
Caroline Michaela Kistorp ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Adipose Tissue ◽  
Side Effects ◽  
Functional Assessment ◽  
Randomised Trial ◽  
Castration Resistant Prostate Cancer ◽  
First Line ◽  
Castration Resistant

IntroductionEnzalutamide and abiraterone acetate plus prednisolone (AAP) are used in combination with androgen-deprivation therapy to further suppress the androgen stimulation of metastatic castration-resistant prostate cancer (mCRPC). First-line mCRPC treatment with enzalutamide and AAP yields similar overall survival and radiographic progression-free survival in phase III trials. Thus, treatment selection relies on patient choice, cost and side effects. The aim of this randomised trial is to investigate differences in fatigue, health-related quality of life (HRQoL) and metabolic side effects in men with mCRPC treated with first-line enzalutamide versus AAP.Methods and analysisIn this ongoing open-label randomised (1:1) clinical trial, enzalutamide is compared with AAP as first-line treatment for men with mCRPC. The primary endpoint is fatigue assessed with the questionnaire Functional Assessment of Chronic Illness Therapy-Fatigue version 4. Secondary endpoints are changes in body composition (ie, fat mass, visceral adipose tissue, subcutaneous adipose tissue and lean body mass assessed with dual energy X-ray absorptiometry), glucose metabolism assessed with a 2-hour oral glucose tolerance test, serum lipids, blood pressure and HRQoL assessed with the questionnaire Functional Assessment of Cancer Therapy-Prostate (FACT-P). All study endpoints are assessed at baseline and 12-week postintervention. Blood and urine samples are collected at baseline and at time of progression on allocated treatment for future investigation of predictive and prognostic biomarkers in prostate cancer treatment. The planned sample size is 170 participants. All participants are recruited from Herlev and Gentofte Hospital, Denmark. Estimated last patient’s last visit is February 2020.Ethics and disseminationThe study received project approval from the National Committee on Health Research Ethics and Danish Data Protection Agency and Danish Medicines Agency (EudraCT no.: 2017-000027-99). The results of the study will be published in peer-reviewed international journals and will be presented at national and international conferences and symposiums.Trial registration numberClinicaltrialsregister.eu (2017-000099-27).

scholarly journals Focal magnetic resonance guided focused ultrasound for prostate cancer: Initial North American experience

2012 ◽  
Vol 6 (6) ◽  
pp. 283 ◽  
Author(s):  
Uri Lindner ◽  
Sangeet Ghai ◽  
Paula Spensieri ◽  
Eugen Hlasny ◽  
Theodorus H. Van der Kwast ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Side Effects ◽  
Magnetic Resonance ◽  
Thermal Ablation ◽  
Focused Ultrasound ◽  
Risk Prostate Cancer ◽  
Low Risk Prostate Cancer ◽  
Tumour Target

The treatment of low-risk prostate cancer is a common clinical dilemma between standard curative whole gland therapy (and its associated quality of life diminishing side effects) and active surveillance (and its low, but real, risk of progression). The goal of focal therapy in low-risk prostate cancer is to achieve the best balance between cancer control and maintenance of quality of life. Magnetic resonance-guided focused ultrasound (MRgFUS) surgery is a non-invasive thermal ablation method that integrates magnetic resonance imaging for target identification, treatment planning and closed-loop control of thermal deposition and focused ultrasound for thermal ablation of the tumour target. This novel transrectal system allows for tumour localization, targeting and monitoring of tumour target ablation in real time, while simultaneously preserving adjacent normal tissue thereby minimizing the side effects of standard curative surgical or radiation therapy. We report the first North American clinical experience of treatment of localized prostate cancer with focal MR-guided transrectal focused ultrasound (clinicaltrial.gov identifier NCT01226576).

Sign in / Sign up

Export Citation Format

Share Document